Lantheus Holdings Inc

LNTH

54.900USD

-0.600-1.08%

Close 08/29, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

34 / 280

Overall Ranking

123 / 4751

Industry

Healthcare Services & Equipment

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

90.154

Target Price

+64.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1013.20.

Undervalued

The company’s latest PE is 13.97, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 82.20M shares, decreasing 5.56% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.82M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.27.

The company's current financial score is 7.89, which is higher than the Healthcare Services & Equipment industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 372.76M, representing a year-over-year increase of 0.75%, while its net profit experienced a year-over-year increase of 44.34%.

Score

Industry at a Glance

Previous score

7.89

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.56

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.23

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Healthcare Services & Equipment industry's average of 2.15. Its current P/E ratio is 14.46, which is 162.58% below the recent high of 37.98 and 0.55% above the recent low of 14.38.

Score

Industry at a Glance

Previous score

5.60

Change

-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/280

No Data

The company’s current earnings forecast score is 8.15, which is higher than the Healthcare Services & Equipment industry's average of 7.66. The average price target for Lantheus Holdings Inc is 92.00, with a high of 130.00 and a low of 63.00.

Score

Industry at a Glance

Previous score

8.15

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.29, which is lower than the Healthcare Services & Equipment industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 71.29 and the support level at 44.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.16

Change

-0.04

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-08-29

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Services & Equipment industry's average of 7.19. The latest institutional shareholding proportion is 120.88%, representing a quarter-over-quarter increase of 0.51%. The largest institutional shareholder is The Vanguard, holding a total of 6.82M shares, representing 10.03% of shares outstanding, with 4.99% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.79M

+0.23%

Janus Henderson Investors

6.26M

-3.88%

The Vanguard Group, Inc.

Star Investors

6.99M

-3.36%

Fidelity Management & Research Company LLC

2.17M

+7.36%

Farallon Capital Management, L.L.C.

6.02M

+13.30%

State Street Global Advisors (US)

2.64M

-0.16%

Geode Capital Management, L.L.C.

1.78M

+5.62%

Wellington Management Company, LLP

909.10K

+306.19%

Westfield Capital Management Company, L.P.

1.59M

+2.19%

T. Rowe Price Investment Management, Inc.

1.41M

-6.42%



1

2



The company's beta value is 0.15. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Lantheus Holdings Inc

LNTH

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insulet Corp

PODD

7.89 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Merit Medical Systems Inc

MMSI

7.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Tenet Healthcare Corp

THC

7.66 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Brightspring Health Services Inc

BTSG

7.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.